Persistent Asset Partners
UTHR icon

Persistent Asset Partners’s United Therapeutics UTHR Stock Holding History

Persistent Asset Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$317K Buy
+121
New +$62.6K 0.09% 150
2026
Q2 		– Sell
-102
Closed -$141K – 915
2026
Q1 		$141K Buy
+102
New +$50.8K 0.05% 219

Other funds holding UTHR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Persistent Asset Partners's UTHR Position: Q3 2026 in Review

Persistent Asset Partners reduced its United Therapeutics (UTHR) stake by 6.2% in Q3 2026, selling an estimated $446K and leaving 13,118 shares worth $7.11M. The position accounts for 1.96% of the portfolio, ranked #11.

Persistent Asset Partners first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $7.58M in Q2 2026. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Persistent Asset Partners held 13,118 shares of United Therapeutics worth $7.11M as of Q3 2026.
  • Persistent Asset Partners sold 863 United Therapeutics shares in Q3 2026, an estimated $446K.
  • United Therapeutics made up 1.96% of Persistent Asset Partners's portfolio in Q3 2026, its #11 holding.
  • Persistent Asset Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Persistent Asset Partners's United Therapeutics position peaked at $7.58M in Q2 2026.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.